

# IN VIVO GENE EDITING OF TAU LOCUS VIA LIPONANOPARTICLE DELIVERY

Tech ID: 33310 / UC Case 2024-026-0

## PATENT STATUS

Patent Pending

## BRIEF DESCRIPTION

Delivery technologies such as lipid nanoparticles (LNP) offer significant advantages over the delivery of free RNA for various RNA therapeutic, vaccine, and basic science applications.

UC Berkeley researchers developed a new class of lipid nanoparticle (LNP) which is effective in delivering various types of nucleic acids in different tissues. The LNP was successfully tested in in-vivo mouse models and therefore poses a significant promise in the gene editing field. The lipid formulation was packaged together with CRISPR Cas9 and a gRNA targeting the endogenous Tau locus. Tau dysregulation is a pathological feature of Alzheimers disease, thus the invention provides a means to intervene in the development of pathological states associated with Tau aggregate formation.

## SUGGESTED USES

» therapeutic applications, particularly ones targeting the Tau locus (e.g., Alzheimers disease)

## ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- ▶ COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR TREATING RNA VIRUS INFECTIONS
- ▶ Genome Editing via LNP-Based Delivery of Efficient and Stable CRISPR-Cas Editors
- ▶ Tissue-Specific Genome Engineering Using CRISPR-Cas9
- ▶ Type III CRISPR-Cas System for Robust RNA Knockdown and Imaging in Eukaryotes
- ▶ Cas9 Variants With Altered DNA Cleaving Activity
- ▶ Cas12-mediated DNA Detection Reporter Molecules
- ▶ Improved guide RNA and Protein Design for CasX-based Gene Editing Platform
- ▶ Cas13a/C2c2 - A Dual Function Programmable RNA Endoribonuclease
- ▶ Miniature Type VI CRISPR-Cas Systems and Methods of Use
- ▶ RNA-directed Cleavage and Modification of DNA using CasY (CRISPR-CasY)
- ▶ Generation of Chimeric RNA with Type III CRISPR-Cas
- ▶ CasX Nickase Designs, Tans Cleavage Designs & Structure
- ▶ Methods and Compositions for Modifying a single stranded Target Nucleic Acid
- ▶ A Dual-RNA Guided CasZ Gene Editing Technology
- ▶ A Protein Inhibitor Of Cas9

## CONTACT

Terri Sale  
terri.sale@berkeley.edu  
tel: 510-643-4219.



## INVENTORS

» Doudna, Jennifer A.

## OTHER INFORMATION

### CATEGORIZED AS

- » **Biotechnology**
- » Genomics
- » **Medical**
- » Disease: Central Nervous System
- » Therapeutics

### RELATED CASES

2024-026-0

- ▶ RNA-directed Cleavage and Modification of DNA using CasX (CRISPR-CasX)
- ▶ Compositions and Methods for Genome Editing
- ▶ IS110 and IS1111 Family RNA-Guided Transposons
- ▶ Variant Cas12a Protein Compositions and Methods of Use
- ▶ In Vitro and In Vivo Genome Editing by LNP Delivery of CRISPR Ribonucleoprotein
- ▶ CRISPR CASY COMPOSITIONS AND METHODS OF USE
- ▶ Single Conjugative Vector for Genome Editing by RNA-guided Transposition
- ▶ Improved Cas12a Proteins for Accurate and Efficient Genome Editing
- ▶ CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
- ▶ Methods Of Use Of Cas12L/CasLambda In Plants
- ▶ Type V CRISPR/CAS Effector Proteins for Cleaving ssDNA and Detecting Target DNA
- ▶ THERMOSTABLE RNA-GUIDED ENDONUCLEASES AND METHODS OF USE THEREOF (GeoCas9)
- ▶ Variant TnpB and wRNA Proteins
- ▶ Efficient Site-Specific Integration Of New Genetic Information Into Human Cells
- ▶ Class 2 CRISPR/Cas COMPOSITIONS AND METHODS OF USE
- ▶ Compositions and Methods of Use for Variant Csy4 Endoribonucleases
- ▶ Immune Cell-Mediated Intercellular Delivery Of Biomolecules
- ▶ Methods and Compositions for Controlling Gene Expression by RNA Processing



University of California, Berkeley Office of Technology Licensing

2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704

Tel: 510.643.7201 | Fax: 510.642.4566

<https://ipira.berkeley.edu/> | [otl-feedback@lists.berkeley.edu](mailto:otl-feedback@lists.berkeley.edu)

© 2023, The Regents of the University of California

[Terms of use](#) | [Privacy Notice](#)